Brainomix Secures Additional £5m Investment to Expand AI Imaging Solutions for Stroke and Lung Fibrosis

The world of healthcare is constantly evolving, with new technologies and innovations emerging every day. One company at the forefront of this revolution is Brainomix, a British biotech firm based in Oxford. Their cutting-edge AI imaging tools for stroke and lung fibrosis have already made a significant impact in the medical field, and now with a new £5m investment, they are poised to make an even bigger impact.

The Investment

Brainomix recently announced that they have extended their Series C round with a new £4.8m investment. This brings their total Series C funding to £18.8m, with the extension led by existing investors Parkwalk Advisors and Hostplus via the IP Group Hostplus Innovation Fund. This round also includes participation from new U.S.-based investor, Modi Ventures.

The Purpose

The additional funding will support Brainomix's expansion into the US market, where they already have an extensive portfolio of FDA-cleared AI imaging solutions. This expansion will also enable the deployment of their AI imaging platforms, Brainomix 360 Stroke and e-Lung, in multiple hospitals.

The Products

Brainomix's flagship product, Brainomix 360 Stroke, is a fully automated imaging platform designed for acute stroke assessment. This solution has been clinically validated and has shown to significantly increase endovascular thrombectomy treatment rates and reduce delays in patient triage and transfer, particularly in primary stroke centers. The company's other product, Brainomix 360 e-Lung, utilizes AI-driven CT biomarkers to identify, monitor, and predict disease progression in pulmonary fibrosis.

The CEO's Perspective

Dr. Michalis Papadakis, co-founder and CEO of Brainomix, believes that the need for hospital technologies that support clinicians at the point of care is crucial. He stated, "Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time." This highlights the importance of their AI imaging solutions in improving patient outcomes.

The Investors' Perspective

Modi Ventures general partner Sahir Ali expressed his excitement about investing in Brainomix and their innovative solutions. He stated, "With e-Lung, Brainomix is developing a truly novel technology to accelerate the diagnosis of fibrosing lung disease, enabling earlier treatment options that can improve patient outcomes."

In Conclusion

The additional £5m investment in Brainomix is a testament to their success and potential in the healthcare industry. With their cutting-edge AI imaging solutions for stroke and lung fibrosis, Brainomix is making a significant impact in the lives of patients and clinicians. This investment will not only support their expansion into the US market but also help them continue to improve and innovate their products.

Source: https://www.uktech.news/news/brainomix-extends-series-c-with-new-5m-investment-20210610